Navigation Links
VCU College of Engineering and Fuzionaire Diagnostics to Pursue Joint Research Applying Novel Radiochemistry Platform to Disease Diagnosis and Drug Discovery

The Virginia Commonwealth University (VCU) College of Engineering and Fuzionaire Diagnostics (Fuzionaire Dx) have executed a research agreement establishing a collaborative program to work toward applications of Fuzionaire Dx’s proprietary radiochemistry platform. The focus of this effort will be to develop new radiopharmaceutical lead candidates and will explore Fuzionaire Dx’s platform as a unique tool for drug discovery.

The versatile chemistry-driven platform, which can radiolabel molecules at record-breaking speed and ambient temperature, has the potential to generate a wide variety of novel radiopharmaceuticals enabling clinicians to better diagnose and treat diseases including cancers, viruses and neurodegenerative and cardiovascular diseases. The platform could also become a powerful new tool for drug discovery, offering valuable insights on the in vivo behavior of pharmaceutical lead compounds at an early stage.

The multiyear research effort will leverage the research and development resources of Fuzionaire Dx and VCU College of Engineering, where chemistry, nuclear medicine, biology and radiology expertise and infrastructure could complement Fuzionaire Dx’s efforts to move its discoveries from bench to bedside.

“This is another example of VCU’s strong relationship with industry and demonstrates our commitment to translating important new science,” said B. Frank Gupton, Ph.D., Floyd D. Gottwald Jr. Chair and chair of the Department of Chemical and Life Science Engineering at VCU College of Engineering. “Everything we do is with an eye toward promoting research into the clinic.”

“Working with Dr. Gupton and VCU gives us access to world class resources and expertise, and Dr. Gupton has an extraordinary track record of productivity and results,” said Anton Toutov, Ph.D., chief science officer of Fuzionaire Dx. “We share a common vision for the future of precision diagnostics and drug discovery and we’re thrilled to be building it together.”

Primary leadership for the collaboration includes Gupton and Toutov, as well as Nick Slavin, CEO of Fuzionaire Dx.

“With his deep industry experience as the former executive director of process development at Boehringer Ingelheim, Dr. Gupton is an ideal collaborator as we develop informed, practical approaches to clinical applications of our technology,” Slavin said.

To learn more about Fuzionaire Dx:

About VCU College of Engineering

The VCU College of Engineering, an innovation front-runner in academics and research, brings real-world education to Central Virginia. Our collaborative and multidisciplinary partnerships prepare undergraduate, master’s and doctoral students for leadership. Part of a premier research university, the VCU College of Engineering enhances regional and global prosperity through cutting-edge developments in tissue engineering, drug delivery, bioinformatics, cybersecurity, mechanical systems and particle science. We make it real by turning great ideas into breakthrough technologies. Our facilities are hubs of discovery, powered by an expanding student body and faculty committed to excellence. We encourage partnering with industry and the community, bringing new collaborators into our projects. Our key research areas include: sustainability and energy engineering; micro and nano electronic systems; pharmaceutical engineering; mechanobiology and regenerative medicine; big data mining; and device design and development.


About Fuzionaire Diagnostics, Inc.

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a radiopharmaceutical company. Our radiolabeling platform aims to unlock the power of PET to help detect and treat any disease.

The primary barriers to better imaging are the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is working to radically improve the scope, safety, use, and cost of PET imaging.

Our patented HetSiFATM compositions, which are synthesized using our alkali metal catalysis, can incorporate radioisotopes into disease-targeting ligands at record-breaking speed.

We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals using a single catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new strategy to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision. The platform also has the potential to become a unique tool for drugmakers, providing critical in vivo pharmacological data earlier in the drug discovery process.

Fuzionaire Dx was co-founded by a team including CEO Nick Slavin, Chief Science Officer Anton Toutov, PhD, and Nova Spivack, and is advised by leading researchers in nuclear medicine and drug discovery.

For more, visit us at:

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. Albert Einstein College of Medicine hosts conference on Jewish genetic research
2. New HIV-1 replication pathway discovered by NYU College of Dentistry researchers
3. Experts from NYU Langone present new research at American College of Rheumatology 2013 Annual Meeting
4. College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases
5. Study identifies high level of food insecurity among college students
6. Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
7. NJITs Newark College of Engineering announces honorees for annual Salute to Excellence
8. IU study: College athletes often sidelined from healthy lifestyle later in life
9. Three UTSA College of Sciences faculty honored at AAAS Annual Meeting
10. MARC travel awards announced for the American College of Sports Medicine 61st Annual Meeting
11. Cancer stem cells under the microscope at Albert Einstein College of Medicine symposium
Post Your Comments:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: